IMOGAM RABIES-HT (Sanofi Pasteur Inc.)
Welcome to the PulseAid listing for the IMOGAM RABIES-HT drug offered from Sanofi Pasteur Inc.. This pharmaceutical is classified as a PLASMA DERIVATIVE. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same PLASMA DERIVATIVE drug type category.
LABELER NAME / MANUFACTURER: | Sanofi Pasteur Inc. |
NON-PROPRIETARY NAME: | HUMAN RABIES VIRUS IMMUNE GLOBULIN |
SUBSTANCE NAME: | HUMAN RABIES VIRUS IMMUNE GLOBULIN |
TYPE: | PLASMA DERIVATIVE |
PHARMA CLASS: | |
ROUTE: | INTRAMUSCULAR |
DOSAGE FORM: | INJECTION, SOLUTION |
MARKETING CATEGORY NAME: | BLA |
START MARKETING DATE: | 1984-04-27 |
END MARKETING DATE: | 0000-00-00 |
IMOGAM RABIES-HT PLASMA DERIVATIVE Details:
Item Description | IMOGAM RABIES-HT from Sanofi Pasteur Inc. |
LABELER NAME: | Sanofi Pasteur Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 150([iU]/mL) |
START MARKETING DATE: | 1984-04-27 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 49281-190_0554e76f-a5a3-4480-998c-62bd4e40c0b8 |
PRODUCT NDC: | 49281-190 |
APPLICATION NUMBER: | BLA103932 |
Other HUMAN RABIES VIRUS IMMUNE GLOBULIN Pharmaceutical Manufacturers / Labelers: